Benefits
Cortisol reduction in moderately stressed adults (Relora RCT)
An RCT in 56 subjects screened for moderate stress found that after 4 weeks of Relora, salivary cortisol exposure was significantly lower (-18%) in the Relora group vs placebo (p<0.05). The strongest evidence-supported claim for Relora — a meaningful effect size for non-pharmaceutical stress intervention.
Mood state improvement (POMS scores)
The same trial: the Relora group showed significantly better Profile of Mood States (POMS) scores vs placebo: Overall Stress -11%, Tension -13%, Depression -20%, Anger -42%, Fatigue -31%, Confusion -27%, Global Mood +11%, Vigor +18%. Multi-dimensional mood improvement in moderately stressed but otherwise healthy adults — useful for everyday stress management.
Mild transitory anxiety reduction (pilot)
A pilot RCT in 40 premenopausal women given Relora 250 mg 3x daily vs placebo for 6 weeks found Relora reduced temporary/transitory anxiety (Spielberger state) but not long-standing anxiety/depression (Spielberger trait). Mixed outcomes: salivary cortisol/amylase, appetite, body morphology, and sleep quality were not significantly changed vs placebo. Important nuance — Relora may help acute/situational stress but not chronic anxiety disorders.
Weight management in stress-eaters
A pilot RCT in overweight premenopausal women (BMI 25-34.9) who eat in response to stress. After 6 weeks of Relora 250 mg 3x daily: no significant weight gain in the treatment group vs the placebo group, which gained 1.5 kg (p<0.01). 75% of placebo were 'gainers' (≥1 kg) vs 37% of the treatment group (p<0.04). Useful for the stress-related eating subgroup specifically, not general weight loss.
Anti-inflammatory and antimicrobial effects (TCM traditional + mechanistic)
Phellodendron bark (Huang Bai) is used in TCM for inflammation, infection, and joint pain — supported by berberine's well-documented antimicrobial activity (vs bacteria, fungi, parasites) and anti-inflammatory NF-κB inhibition. See the Berberine entry for detailed evidence on the principal active compound. Phellodendron's berberine content (~1-2%) is substantially less than Goldenseal or Barberry concentrations.
Mechanism of action
GABAergic activity and HPA axis modulation (Relora/honokiol mediated)
The Relora cortisol-reducing effect is primarily attributed to Magnolia's honokiol (GABA receptor modulator) rather than Phellodendron alone. Phellodendron contributes synergistic effects via berberine. Combined product modulates HPA axis stress response — reducing CRH/ACTH/cortisol cascade. Animal models confirm anxiolytic effect via GABA pathway.
Berberine — AMPK activation, antimicrobial, lipid effects
Berberine activates AMPK (insulin sensitivity, glucose/lipid metabolism), inhibits multiple bacteria/fungi/parasites, and reduces inflammation via NF-κB inhibition. Phellodendron is one of multiple traditional berberine sources (alongside Coptis chinensis, Goldenseal, Barberry). See Berberine entry for detailed mechanism.
Anti-inflammatory NF-κB inhibition
Berberine and obacunone inhibit NF-κB activation, reducing inflammatory cytokine production. Mechanism for traditional anti-inflammatory uses (joint pain, GI inflammation, skin conditions) and complementary to Magnolia's effects in Relora combination.
5-HT and dopamine modulation (mood effects)
Relora's mood-enhancing effects involve serotonin and dopamine modulation in addition to cortisol reduction. Animal studies show Relora components enhance neurogenesis and BDNF expression — relevant to depression/mood applications. Combined effect of multiple components likely.
Clinical trials
Randomized double-blind placebo-controlled trial (Talbott SM, Talbott JA, J Int Soc Sports Nutr 10(1):37, doi:10.1186/1550-2783-10-37).
56 subjects (35 men, 21 women) screened for moderate stress, supplemented with Relora (Magnolia officinalis + Phellodendron amurense bark extracts) or placebo for 4 weeks.
Relora group: salivary cortisol exposure -18% (p<0.05) vs placebo. Significantly better mood: Overall Stress -11%, Tension -13%, Depression -20%, Anger -42%, Fatigue -31%, Confusion -27%, Global Mood +11%, Vigor +18%. Authors concluded Relora reduces cortisol exposure and perceived daily stress while improving multiple mood parameters. Strongest single trial supporting Phellodendron-containing product for stress/mood applications.
Pilot, double-blind, placebo-controlled clinical trial (Kalman DS, Feldman S, Feldman R, Schwartz HI, Krieger DR, Nutr J 7:11, doi:10.1186/1475-2891-7-11).
40 healthy overweight (BMI 25-34.9) premenopausal women (ages 20-50) who eat more in response to stress and score above national mean for women on self-reporting anxiety. Randomized to Relora 250 mg 3x daily or placebo for 6 weeks.
Relora effective for reducing temporary/transitory anxiety (Spielberger state questionnaire) vs placebo. Relora not effective for long-standing anxiety or depression (Spielberger trait). Salivary cortisol, amylase, appetite, body morphology, sleep not significantly changed. Mixed findings — Relora may help acute/situational anxiety but not chronic anxiety disorders. Important nuance for clinical positioning.
Randomized double-blind placebo-controlled clinical study (Garrison R, Chambliss WG 2006, Altern Ther Health Med 12(1):50-54).
Overweight (BMI 25-34.9) premenopausal female adults (ages 20-50) who typically eat more in stressful situations and scored above national mean for women on self-reported anxiety. Two 250-mg capsules or identical placebo capsules 3x daily for 6 weeks. Outcomes: salivary cortisol, weight change, psychological measures.
28 subjects completed. Significant weight gain in placebo group (+1.5 kg, p<0.01); NO significant weight gain in Relora group (+0 kg, p=0.89). 75% of placebo were 'gainers' (≥1 kg) vs 37% of treatment group (p<0.04). Useful for stress-related eating subgroup specifically — not general weight loss intervention.